US Patent

US10548871 — Low-dose doxepin formulations and methods of making and using the same

Method of Use · Assigned to Currax Pharmaceuticals LLC · Expires 2028-04-11 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects low-dose oral doxepin pharmaceutical formulations used to promote sleep.

USPTO Abstract

The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.

Drugs covered by this patent

doxepin-hydrochloride (DOXEPIN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-620`	—	doxepin-hydrochloride
`U-620`	—	doxepin-hydrochloride

Patent Metadata

Patent number: US10548871
Jurisdiction: US
Classification: Method of Use
Expires: 2028-04-11
Drug substance claim: No
Drug product claim: No
Assignee: Currax Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.